(Q40053620)

English

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo

scientific article published on 9 November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 September 2017

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo (English)

1 reference

Europe PubMed Central

16 September 2017

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

author name string

Nishitha Reddy

1

1 reference

Europe PubMed Central

16 September 2017

Francisco J Hernandez-Ilizaliturri

2

1 reference

Europe PubMed Central

16 September 2017

George Deeb

3

1 reference

Europe PubMed Central

16 September 2017

Mark Roth

4

1 reference

Europe PubMed Central

16 September 2017

Mary Vaughn

5

1 reference

Europe PubMed Central

16 September 2017

Joy Knight

6

1 reference

Europe PubMed Central

16 September 2017

Paul Wallace

7

1 reference

Europe PubMed Central

16 September 2017

Myron S Czuczman

8

1 reference

Europe PubMed Central

16 September 2017

language of work or name

0 references

publication date

9 November 2007

1 reference

Europe PubMed Central

16 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

16 September 2017

140

1 reference

Europe PubMed Central

16 September 2017

36-45

1 reference

Europe PubMed Central

16 September 2017

1

1 reference

Europe PubMed Central

16 September 2017

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

MCP-1 modulates chemotaxis by follicular lymphoma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Efficacy of lenalidomide in myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06841.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2007.06841.X

1 reference

Europe PubMed Central

16 September 2017

1 reference

Europe PubMed Central

16 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40053620&oldid=1883326034"